



Christian Karagiannidis
Stephan Strassmann
Alois Philipp
Thomas Müller
Wolfram Windisch

Veno-venous extracorporeal CO₂ removal improves pulmonary hypertension in acute exacerbation of severe COPD

Accepted: 9 June 2015
Published online: 23 June 2015
© Springer-Verlag Berlin Heidelberg and ESICM 2015

C. Karagiannidis and S. Strassmann contributed equally to this work.

Dear Editor,
Acute exacerbation of chronic obstructive pulmonary disease (COPD) typically leads to acute hypercapnic respiratory failure with respiratory acidosis, which requires the augmentation of alveolar ventilation by mechanical support. At best, non-invasive ventilation is implemented early in these patients as it reduces intubation rate and intubation-related complications, and, importantly, mortality. Recently, veno-venous extracorporeal CO₂ removal (vv-ECCO₂R) has been shown to rapidly correct even severe respiratory acidosis [1], and this technique is currently under investigation as an adjunct to treat severe COPD patients. Here, vv-ECCO₂R is aimed at avoiding intubation or at reducing the time spent on invasive mechanical ventilation [2]. In ARDS patients there is some new evidence that vv-ECCO₂R provides additional benefit by decreasing elevated systolic pulmonary artery pressure

(PAPs) both in animals [3] and in patients, where this effect reportedly depends on the amount of CO₂ removed [4]. Even though a strong correlation between pulmonary artery dilatation and severe COPD exacerbation was shown previously [5], the clinical consequences of an increased PAP occurring during COPD exacerbation are still unclear, and the impact of vv-ECCO₂R on PAP in COPD exacerbation still needs to be elucidated.

We report on five patients (mean age 52 ± 13 years, four female) with severe COPD exacerbation and invasive mechanical ventilation following intubation, in whom vv-ECCO₂R was initiated to reduce intubation time and in whom pulmonary artery catheterization was used for regular hemodynamic monitoring. All patients had failed at least two spontaneous breathing trials within 48 h before vv-ECCO₂R was considered according to the study protocol of the “PALPTM-COPD Trial” (www.clinicaltrials.gov: NCT02107222), which is planned to start in the near future.

During vv-ECCO₂R mean PAP decreased from 36.8 ± 5.6 (baseline) to 27.0 ± 7.0 (15 min), to 26.6 ± 6.1 (30 min), to 24.4 ± 3.4 (45 min), and, eventually, to 22.8 ± 2.8 (60 min) mmHg (Fig. 1), while

ventilator settings used for invasive ventilation were adapted accordingly. The mean blood flow used for vv-ECCO₂R was 2.0 ± 0.5 L/min, and the mean sweep gas flow was 7.6 ± 1.7 L/min using a FiO₂ of 1.0. During 60 min of vv-ECCO₂R mean PaCO₂ decreased from 95.0 ± 25.8 to 53.2 ± 13.7 mmHg, while mean pH increased from 7.27 ± 0.08 to 7.49 ± 0.09. At baseline mean cardiac index (CI) was 4.0 ± 0.49 L/min/m² and mean wedge pressure was 16.4 ± 2.9 mmHg, while further CI measurements during vv-ECCO₂R were not reliable as a result of the artificially induced jet blood flow next to the right atrium. Finally, all patients were extubated successfully; one patient had to be reintubated and required tracheostomy and prolonged weaning.

To our knowledge, this case series shows for the first time that vv-ECCO₂R has not only the potential to rapidly correct respiratory acidosis by lowering high PaCO₂ values but also to reduce elevated mean PAP values in severe COPD significantly. Mean PAP values were substantially elevated in our patients with exacerbated COPD and could be normalized within 1 h of vv-ECCO₂R. This may be of major clinical importance given the known deleterious effects of acute pulmonary hypertension in patients




Fig. 1 Time course of mean pulmonary arterial pressure (PAP) after vv-ECCO₂R initiation in severe COPD

with respiratory failure. Consequently, further studies should systematically investigate the impact of vv-ECCO₂R on right heart function in patients with pulmonary hypertension during severe exacerbation of COPD that requires mechanical ventilation to treat respiratory acidosis.

Compliance with ethical standards

Conflicts of interest C.K. received travel grants and lecture fees from Maquet, Rastatt, Germany; S.S. and A.P. have no conflicts of interest; T.M. received travel grants from Maquet, Rastatt, Germany; W.W. received fees for advisory board meetings and lectures from Maquet, Rastatt, Germany.

References

1. Karagiannidis C, Kampe KA, Sipmann FS, Larsson A, Hedenstierna G, Windisch W, Mueller T (2014) Venovenous extracorporeal CO₂ removal for the treatment of severe respiratory acidosis: pathophysiological and technical considerations. *Crit Care* 18:R124
2. Abrams DC, Brenner K, Burkart KM, Agerstrand CL, Thomashow BM, Bacchetta M, Brodie D (2013) Pilot study of extracorporeal carbon dioxide removal to facilitate extubation and ambulation in exacerbations of chronic obstructive pulmonary disease. *Ann Am Thorac Soc* 10:307–314
3. Morimont P, Guiot J, Desai V, Tchanasato V, Janssen N, Cagnina A, Hella D, Blaffart F, Defraigne JO, Lambermont B (2015) Venovenous extracorporeal CO₂ removal improves pulmonary hemodynamics in a porcine ARDS model. *Acta Anaesthesiol Scand* 59:448–456
4. Schmidt M, Tachon G, Devilliers C, Muller G, Hekimian G, Brechot N, Merceron S, Luyt CE, Trouillet JL, Chastre J, Leprince P, Combes A (2013) Blood oxygenation and decarboxylation determinants during venovenous ECMO for respiratory failure in adults. *Intensive Care Med* 39:838–846
5. Wells JM, Washko GR, Han MK, Abbas N, Nath H, Marmar AJ, Regan E, Bailey WC, Martinez FJ, Westfall E, Beaty TH, Curran-Everett D, Curtis JL, Hokanson JE, Lynch DA, Make BJ, Crapo JD, Silverman EK, Bowler RP, Dransfield MT, COPD Gene Investigators, ECLIPSE Study Investigators (2012) Pulmonary arterial enlargement and acute exacerbations of COPD. *N Engl J Med* 367:913–921

C. Karagiannidis (✉) · S. Strassmann · W. Windisch
Department of Pneumology and Critical Care Medicine, Cologne-Merheim Hospital, Kliniken der Stadt Köln gGmbH, Witten/Herdecke University Hospital, Ostmerheimer Strasse 200, 51109 Cologne, Germany
e-mail: karagiannidisc@kliniken-koeln.de
Tel.: +49 221 8907 18809

A. Philipp
Department of Cardiothoracic Surgery, University Medical Center, Regensburg, Germany

T. Müller
Department of Internal Medicine II, University Hospital of Regensburg, Franz-Josef-Strauss-Allee 11, 93053 Regensburg, Germany